Mark Moody

Mark Moody

Company: Activate Therapeutics

Job title: Chief Operating Officer

Seminars:

Nanomedicine Formulations for TLR Agonist Drug Combinations 3:00 pm

Activate’s lipogel nanoparticles (LgNPs) can co-package combinations of TLR agonists and immune-oncology drugs to provide sustained delivery of these drugs to the tumor while reducing systemic exposure and associated toxicity These LgNPs are phagocytized by macrophages and dendritic cells – delivering TLR agonists to the endosome where TLR targets reside TLR-based combination therapies have been…Read more

day: Day Two

Panel Discussion: What is the Best Modality & Delivery Approach to PRR-Pathway Targeting? 1:30 pm

Discussing safety profiles, dosing and scheduling considerations, therapeutic window Dissecting drug design approach for systemic and intratumoral Understanding possible regulatory considerations Mechanisms of action that are leading to strong efficacy Enhancing administration and delivery of therapies for safe and effective clinical outcomes Systemic delivery technologies vs intra-tumoral delivery technologiesRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.